Tenaya Therapeutics, Inc.
Tenaya Therapeutics (Nasdaq: TNYA) is a clinical-stage biotechnology company developing therapies intended to address the underlying causes of heart disease, with a focus on genetically defined cardiomyopathies. Its lead candidates are TN-201, an AAV9-based gene therapy for MYBPC3-associated hypertrophic… From the company’s description.
In fiscal 2025, Tenaya Therapeutics, Inc. reported a net loss of $90.60M. Operations used $68.26M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Tenaya Therapeutics, Inc. does
In the company’s own words
Tenaya Therapeutics (Nasdaq: TNYA) is a clinical-stage biotechnology company developing therapies intended to address the underlying causes of heart disease, with a focus on genetically defined cardiomyopathies. Its lead candidates are TN-201, an AAV9-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, an AAV9-based gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy; both are in Phase 1b/2 clinical testing. TN-301 is a small-molecule HDAC6 inhibitor that completed Phase 1 testing and is being explored for heart failure with preserved ejection fraction and other cardiac, muscular and metabolic conditions. Tenaya also advances earlier-stage programs using gene addition, gene editing, gene silencing and cellular regeneration. The company combines genetic target discovery, human heart-disease models, AAV design and manufacturing capabilities. In 2026, it entered a research collaboration with Alnylam to identify and validate cardiovascular gene targets. Tenaya was founded to build an integrated biopharmaceutical business, with plans to develop and potentially commercialize therapies for rare conditions and pursue partners for larger indications.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1858848
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Tenaya Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Tenaya Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Tenaya Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Tenaya Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Tenaya Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”